Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Core Insights - Beyond Air, Inc. is focused on utilizing high-dose inhaled nitric oxide (iNO) as a potential broad-spectrum antimicrobial therapy for respiratory infections, as highlighted in a recent independent review article [1][2][3] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to improving patient outcomes in respiratory illnesses, neurological disorders, and solid tumors [4] - The company has received FDA approval and CE Mark for its LungFit PH system, which treats hypoxic respiratory failure in neonates [4] - Beyond Air is advancing other LungFit systems in clinical trials targeting severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Research and Development - An independent review article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various clinical settings, including pneumonia and COVID-19 [2] - The review outlines the unique multimodal activities of high-dose iNO, such as direct microbial killing, biofilm disruption, and inflammation reduction [2] - Future research opportunities are identified in areas like hospital-acquired pneumonia and tuberculosis, where new therapeutic tools are urgently needed [2] Market Potential - The CEO of Beyond Air expressed optimism about the recognition of high-dose iNO as a transformative treatment for respiratory infections, indicating a growing body of evidence supporting its use [3] - The publication of the review article is expected to catalyze further scientific research and accelerate clinical development of high-dose iNO [3] Product Details - Beyond Air's LungFit system is a cylinder-free delivery system capable of generating nitric oxide from ambient air at concentrations ranging from 1 ppm to 80 ppm [6] - The system is designed to replace traditional high-pressure nitric oxide cylinders, offering operational advantages in hospital settings [6][7] - LungFit can deliver nitric oxide at concentrations above 80 ppm for treating severe acute lung infections in both hospital and home settings [7]